14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
When an inspector from the Occupational Safety and Health Administration (OSHA) shows up at your wor...
Read More >
The following alert is directed to organizations with a presence in the UK or who anticipate the nee...
Read More >
In light of a landmark decision from France’s highest court, acquiring companies will have to give ...
Read More >
The Situation: Australia's corporate regulator, the Australian Securities and Investments Commission...
Read More >
If an employment contract is illegal for some reason both the employer and employee may be prevented...
Read More >
The Boston Globe has a well-reported story out this morning on the United Food and Commercial Worker...
Read More >